<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>NMPA</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>China launches long-awaited drug data protection rules </title>
      <description>
        <![CDATA[China’s National Medical Products Administration has issued final implementation measures for drug trial data protection that mark a significant step toward aligning China’s pharmaceutical intellectual property framework with global standards.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731647</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731647-china-launches-long-awaited-drug-data-protection-rules</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Devices/cybersecurity-data-lock.webp?t=1588286982" type="image/png" medium="image" fileSize="321597">
        <media:title type="plain">Cybersecurity data lock</media:title>
      </media:content>
    </item>
    <item>
      <title>Longbio to raise HK$1.4B in Hong Kong IPO for immunology work</title>
      <description>
        <![CDATA[Chinese biotech Longbio Pharma Co. Ltd. announced its IPO on the Hong Kong Stock Exchange to raise HK$1.362 billion (US$174 million) to progress its lead candidate, LP-003, a next-generation anti-IgE antibody.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731646</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731646-longbio-to-raise-hk14b-in-hong-kong-ipo-for-immunology-work</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/HKEX-illustration.webp?t=1665175609" type="image/png" medium="image" fileSize="332663">
        <media:title type="plain">HKEX on phone, digital stock chart</media:title>
        <media:description type="plain">Credit: piter2121 - stock.adobe.com</media:description>
      </media:content>
    </item>
    <item>
      <title>China deals highlight biopharma evolution, reports LEK</title>
      <description>
        <![CDATA[In 2025, China’s outbound life sciences and biopharma deals reached nearly $100 billion, about 12 times the level seen in 2021, underscoring how quickly global appetite for Chinese assets has accelerated, according to a recent report by L.E.K. Consulting. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/731530</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731530-china-deals-highlight-biopharma-evolution-reports-lek</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/China-deals-illustration.webp?t=1780424261" type="image/jpeg" medium="image" fileSize="130740">
        <media:title type="plain">China map/flag with silhouettes of business people</media:title>
      </media:content>
    </item>
    <item>
      <title>China launches long-awaited drug data protection rules </title>
      <description>
        <![CDATA[China’s National Medical Products Administration has issued final implementation measures for drug trial data protection that mark a significant step toward aligning China’s pharmaceutical intellectual property framework with global standards.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731457</guid>
      <pubDate>Fri, 29 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731457-china-launches-long-awaited-drug-data-protection-rules</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Devices/cybersecurity-data-lock.webp?t=1588286982" type="image/png" medium="image" fileSize="321597">
        <media:title type="plain">Cybersecurity data lock</media:title>
      </media:content>
    </item>
    <item>
      <title>TROP2 ADCs progress into first-line for lung, breast cancers</title>
      <description>
        <![CDATA[Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for the targeted class of cancer therapeutics.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731648</guid>
      <pubDate>Thu, 28 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731648-trop2-adcs-progress-into-first-line-for-lung-breast-cancers</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Floating-antibody-drug-conjugates.webp?t=1737562655" type="image/jpeg" medium="image" fileSize="131818">
        <media:title type="plain">Floating antibody drug conjugates</media:title>
      </media:content>
    </item>
    <item>
      <title>Longbio to raise HK$1.4B in Hong Kong IPO for immunology work</title>
      <description>
        <![CDATA[Chinese biotech Longbio Pharma Co. Ltd. announced its IPO on the Hong Kong Stock Exchange to raise HK$1.362 billion (US$174 million) to progress its lead candidate, LP-003, a next-generation anti-IgE antibody.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731445</guid>
      <pubDate>Thu, 28 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731445-longbio-to-raise-hk14b-in-hong-kong-ipo-for-immunology-work</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/HKEX-illustration.webp?t=1665175609" type="image/png" medium="image" fileSize="332663">
        <media:title type="plain">HKEX on phone, digital stock chart</media:title>
        <media:description type="plain">Credit: piter2121 - stock.adobe.com</media:description>
      </media:content>
    </item>
    <item>
      <title>TROP2 ADCs progress into first-line for lung, breast cancers</title>
      <description>
        <![CDATA[Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for the targeted class of cancer therapeutics.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731444</guid>
      <pubDate>Thu, 28 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731444-trop2-adcs-progress-into-first-line-for-lung-breast-cancers</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Floating-antibody-drug-conjugates.webp?t=1737562655" type="image/jpeg" medium="image" fileSize="131818">
        <media:title type="plain">Floating antibody drug conjugates</media:title>
      </media:content>
    </item>
    <item>
      <title>Tennor’s $80M Hong Kong IPO to fund antibacterial drug pipeline </title>
      <description>
        <![CDATA[Antimicrobial-focused Tennor Therapeutics Ltd. will debut in Hong Kong May 22, having priced a HK$626.84 million (US$80 million) IPO. The Suzhou, China-based biotech is waiting on China’s National Medical Products Administration approval of lead asset rifasutenizol (TNP-2198), which has potential to become the first targeted combination regimen to treat <em>H. pylori</em> infection.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731470</guid>
      <pubDate>Tue, 26 May 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731470-tennors-80m-hong-kong-ipo-to-fund-antibacterial-drug-pipeline</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Antibiotics-petri-dish.webp?t=1588349786" type="image/png" medium="image" fileSize="499611">
        <media:title type="plain">Petri dish and capsules</media:title>
      </media:content>
    </item>
    <item>
      <title>Biotle’s FcRn inhibitor BTL-203 cleared for clinic in China</title>
      <description>
        <![CDATA[Biotle has received a clinical trial notice from China’s National Medical Products Administration (NMPA) for its IND application for BTL-203, the company’s bispecific FcRn inhibitor being developed for the treatment of multiple autoimmune diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731272</guid>
      <pubDate>Tue, 26 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731272-biotles-fcrn-inhibitor-btl-203-cleared-for-clinic-in-china</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Green-and-red-bispecific-antibodies.webp?t=1741632039" type="image/jpeg" medium="image" fileSize="108053">
        <media:title type="plain">Green and red bispecific antibodies</media:title>
      </media:content>
    </item>
    <item>
      <title>Tennor’s $80M Hong Kong IPO to fund antibacterial drug pipeline </title>
      <description>
        <![CDATA[Antimicrobial-focused Tennor Therapeutics Ltd. will debut in Hong Kong May 22, having priced a HK$626.84 million (US$80 million) IPO. The Suzhou, China-based biotech is waiting on China’s National Medical Products Administration approval of lead asset rifasutenizol (TNP-2198), which has potential to become the first targeted combination regimen to treat <em>H. pylori</em> infection.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731374</guid>
      <pubDate>Thu, 21 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731374-tennors-80m-hong-kong-ipo-to-fund-antibacterial-drug-pipeline</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Antibiotics-petri-dish.webp?t=1588349786" type="image/png" medium="image" fileSize="499611">
        <media:title type="plain">Petri dish and capsules</media:title>
      </media:content>
    </item>
    <item>
      <title>Vincentage’s oral GLP-1 meets phase III obesity endpoints   </title>
      <description>
        <![CDATA[Vincentage Pharma Co. Ltd.’s once-daily oral small-molecule GLP-1 receptor agonist, VCT-220, met the primary endpoints in a pivotal phase III trial in overweight or obese patients in China. Based on the top-line data, the Chengdu, China-based company plans to submit an NDA for chronic weight management to China’s National Medical Products Administration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731330</guid>
      <pubDate>Tue, 19 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731330-vincentages-oral-glp-1-meets-phase-iii-obesity-endpoints</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Oral-medication.webp?t=1652383335" type="image/png" medium="image" fileSize="350602">
        <media:title type="plain">Oral medication</media:title>
      </media:content>
    </item>
    <item>
      <title>China’s NMPA clears KAT6 inhibitor SYH-2095 for clinic</title>
      <description>
        <![CDATA[China’s National Medical Products Administration (NMPA) has granted clinical trial clearance to SYH-2095 tablets, a novel lysine acetyltransferase 6 (KAT6) inhibitor codeveloped by CSPC Pharmaceutical Group Ltd. and Hangzhou Innogate Pharma Co. Ltd. for the treatment of advanced malignant tumors. SYH-2095 received IND clearance in the U.S. last month.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731159</guid>
      <pubDate>Tue, 19 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731159-chinas-nmpa-clears-kat6-inhibitor-syh-2095-for-clinic</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Wooden-stamp-with-China-flag.webp?t=1728932051" type="image/jpeg" medium="image" fileSize="185893">
        <media:title type="plain">Wooden stamp with China flag</media:title>
      </media:content>
    </item>
    <item>
      <title>China med-tech raises: Star Sports’ $105M IPO; Cofoe nabs $133M</title>
      <description>
        <![CDATA[Star Sports Medicine Co. Ltd. debuted on the Hong Kong Stock Exchange with an HK$829.55 million (US$105.86 million) IPO May 5, with shares closing about 118% higher on the first day.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731227</guid>
      <pubDate>Tue, 12 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731227-china-med-tech-raises-star-sports-105m-ipo-cofoe-nabs-133m</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/HK-Star-Sports-IPO-5-6.webp?t=1778095416" type="image/jpeg" medium="image" fileSize="144071">
        <media:title type="plain">​Star Sports Medicine HKEX IPO ceremony</media:title>
        <media:description type="plain">Star Sports Medicine's IPO ceremony on May 5.
Credit: HKEX; x.com – @HKEXGroup</media:description>
      </media:content>
    </item>
    <item>
      <title>Metis Techbio, Impact Tx cleared for Hong Kong IPOs</title>
      <description>
        <![CDATA[Metis Techbio Co. Ltd. is seeking a potential HK$2.11 billion (US$270 million) raise through a stock sale May 13, marking the largest biotech raise on the Hong Kong Stock Exchange this year to date. Hangzhou, China-based Metis is an AI-based nanoparticle drug formulation and delivery-focused company. Synthetic lethality-based cancer drugmaker Impact Therapeutics Inc., of Shanghai, plans to debut on the same day with a US$117 million IPO.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731048</guid>
      <pubDate>Tue, 12 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731048-metis-techbio-impact-tx-cleared-for-hong-kong-ipos</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Businessman-and-IPO-virtual-screen.webp?t=1717791671" type="image/jpeg" medium="image" fileSize="332138">
        <media:title type="plain">Businessman and IPO virtual screen</media:title>
      </media:content>
    </item>
    <item>
      <title>Innocare Pharma’s ICP-B208 gains IND clearance in China</title>
      <description>
        <![CDATA[Beijing Innocare Pharma Tech Co. Ltd. has received IND approval from China’s National Medical Products Administration (NMPA) for ICP-B208, an antibody-drug conjugate targeting CDH17, which is highly expressed in gastrointestinal cancers, including colorectal, gastric and biliary tract cancers and pancreatic ductal adenocarcinoma.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730932</guid>
      <pubDate>Thu, 07 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730932-innocare-pharmas-icp-b208-gains-ind-clearance-in-china</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/3D-illustration-of-human-digestive-system.webp?t=1709246262" type="image/jpeg" medium="image" fileSize="171684">
        <media:title type="plain">3D illustration of human digestive system</media:title>
      </media:content>
    </item>
    <item>
      <title>China med-tech raises: Star Sports’ $105M IPO; Cofoe nabs $133M</title>
      <description>
        <![CDATA[Star Sports Medicine Co. Ltd. debuted on the Hong Kong Stock Exchange with an HK$829.55 million (US$105.86 million) IPO May 5, with shares closing about 118% higher on the first day.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730868</guid>
      <pubDate>Wed, 06 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730868-china-med-tech-raises-star-sports-105m-ipo-cofoe-nabs-133m</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/HK-Star-Sports-IPO-5-6.webp?t=1778095416" type="image/jpeg" medium="image" fileSize="144071">
        <media:title type="plain">​Star Sports Medicine HKEX IPO ceremony</media:title>
        <media:description type="plain">Star Sports Medicine's IPO ceremony on May 5.
Credit: HKEX; x.com – @HKEXGroup</media:description>
      </media:content>
    </item>
    <item>
      <title>Simcere Zaiming’s SIM-0613 cleared to enter clinic in China</title>
      <description>
        <![CDATA[Simcere Zaiming Pharmaceutical Co. Ltd.’s SIM-0613 for injection has received clinical trial approval from China’s National Medical Products Administration (NMPA), enabling initiation of a clinical trial for advanced solid tumors.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730909</guid>
      <pubDate>Wed, 06 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730909-simcere-zaimings-sim-0613-cleared-to-enter-clinic-in-china</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-cell-antibody-attack.webp?t=1588880107" type="image/png" medium="image" fileSize="559822">
        <media:title type="plain">Antibodies attacking cancer cell </media:title>
      </media:content>
    </item>
    <item>
      <title>Bio Korea 2026: US policy risks shift to execution framework</title>
      <description>
        <![CDATA[Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies can tailor regulatory strategies early, and across the entire development cycle.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730926</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730926-bio-korea-2026-us-policy-risks-shift-to-execution-framework</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Strategy-compass.webp?t=1777923242" type="image/jpeg" medium="image" fileSize="113016">
        <media:title type="plain">Strategy compass</media:title>
      </media:content>
    </item>
    <item>
      <title>Bio Korea 2026: US policy risks shift to execution framework</title>
      <description>
        <![CDATA[Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies can tailor regulatory strategies early, and across the entire development cycle.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730835</guid>
      <pubDate>Mon, 04 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730835-bio-korea-2026-us-policy-risks-shift-to-execution-framework</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Strategy-compass.webp?t=1777923242" type="image/jpeg" medium="image" fileSize="113016">
        <media:title type="plain">Strategy compass</media:title>
      </media:content>
    </item>
    <item>
      <title>Xuanzhu shares dip despite phase III ALK inhibitor data</title>
      <description>
        <![CDATA[Xuanzhu Biopharmaceutical Co. Ltd. reported positive data from a local phase III study of dirozalkib (Xuan Fei Ning), an ALK inhibitor approved in China to treat patients with advanced non-small-cell lung cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730579</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730579-xuanzhu-shares-dip-despite-phase-iii-alk-inhibitor-data</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Lung-cancer-illustration.webp?t=1621625770" type="image/png" medium="image" fileSize="543175">
        <media:title type="plain">Lung cancer illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Biogen amasses full felzartamab rights with $850M TJ deal </title>
      <description>
        <![CDATA[Biogen Inc. has consolidated full global rights to felzartamab through an $850 million deal with TJ Biopharma Co. Ltd. April 20, closing the chapter on a complex 10-year license saga. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730485</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730485-biogen-amasses-full-felzartamab-rights-with-850m-tj-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Global-handshake-silhouette.webp?t=1670353285" type="image/png" medium="image" fileSize="178881">
        <media:title type="plain">Global handshake silhouette</media:title>
      </media:content>
    </item>
    <item>
      <title>Xuanzhu shares dip despite phase III ALK inhibitor data</title>
      <description>
        <![CDATA[Xuanzhu Biopharmaceutical Co. Ltd. reported positive data from a local phase III study of dirozalkib (Xuan Fei Ning), an ALK inhibitor approved in China to treat patients with advanced non-small-cell lung cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730470</guid>
      <pubDate>Mon, 20 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730470-xuanzhu-shares-dip-despite-phase-iii-alk-inhibitor-data</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Lung-cancer-illustration.webp?t=1621625770" type="image/png" medium="image" fileSize="543175">
        <media:title type="plain">Lung cancer illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>CSPC’s SYS-6051 cleared for clinic in China for solid tumors</title>
      <description>
        <![CDATA[CSPC Pharmaceutical Group Ltd.’s SYS-6051 has gained clinical trial clearance from China’s National Medical Products Administration (NMPA) for advanced solid tumors. SYS-6051 is a human tissue factor-targeted antibody-drug conjugate that binds to tissue factor expressed on the surface of tumor cells.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730429</guid>
      <pubDate>Thu, 16 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730429-cspcs-sys-6051-cleared-for-clinic-in-china-for-solid-tumors</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Antibody-drug-conjugates-ADCs-3D.webp?t=1751620465" type="image/jpeg" medium="image" fileSize="160333">
        <media:title type="plain">3D rendering of an antibody-drug conjugate</media:title>
      </media:content>
    </item>
    <item>
      <title>China’s NMPA accepts Mabwell’s IND application for 6MW5311</title>
      <description>
        <![CDATA[Mabwell (Shanghai) Bioscience Co. Ltd.’s has announced IND acceptance by China’s National Medical Products Administration (NMPA) for the company’s LILRB4/CD3 T-cell engager bispecific antibody 6MW5311. The drug candidate is being developed for hematologic malignancies, specifically acute myeloid leukemia (AML), chronic myelomonocytic leukemia and multiple myeloma.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730428</guid>
      <pubDate>Thu, 16 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730428-chinas-nmpa-accepts-mabwells-ind-application-for-6mw5311</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/AML-cells-acute-myeloid-leukemia.webp?t=1663340307" type="image/png" medium="image" fileSize="1258935">
        <media:title type="plain">Microscopic image of acute myeloid leukemia (AML) cells.</media:title>
        <media:description type="plain">Acute myeloid leukemia cells. Credit: Cincinnati Children's
</media:description>
      </media:content>
    </item>
    <item>
      <title>Mabwell announces Chinese clinical trial clearance for SST-001</title>
      <description>
        <![CDATA[Mabwell (Shanghai) Bioscience Co. Ltd. has announced that SST-001 (18F-FD4), an α-synuclein-targeted PET tracer developed by Mabwell’s incubated company Synusight Biotech, has received clinical trial clearance from China’s National Medical Products Administration (NMPA). The planned phase I trial will enroll healthy volunteers, patients with multiple system atrophy (MSA), and patients with Parkinson’s disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730374</guid>
      <pubDate>Wed, 15 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730374-mabwell-announces-chinese-clinical-trial-clearance-for-sst-001</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Radiopharmaceutical-illustration.webp?t=1680558525" type="image/png" medium="image" fileSize="129994">
        <media:title type="plain">Radiopharmaceutical illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Fosun gains clinical trial approval in China for FXB-0871</title>
      <description>
        <![CDATA[Fosun Pharmaceutical (Group) Co. Ltd. has received the approval from China’s National Medical Products Administration (NMPA) to initiate a clinical trial of FXB-0871 (TEV-56278) for the treatment of locally advanced or metastatic solid tumors.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730093</guid>
      <pubDate>Thu, 02 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730093-fosun-gains-clinical-trial-approval-in-china-for-fxb-0871</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-tumor-blood-vessels.webp?t=1691420296" type="image/jpeg" medium="image" fileSize="242637">
        <media:title type="plain">3D illustration of tumor</media:title>
      </media:content>
    </item>
    <item>
      <title>Innovent’s IBI-302 meets phase III endpoints in neovascular AMD </title>
      <description>
        <![CDATA[Innovent Biologics Inc.’s efdamrofusp alfa (IBI-302) met the primary endpoint in the phase III Star trial in neovascular age-related macular degeneration (nAMD), and the Suzhou, China-based company will submit an NDA to China’s National Medical Products Administration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730089</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730089-innovents-ibi-302-meets-phase-iii-endpoints-in-neovascular-amd</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Amsler-grid-test.webp?t=1627064994" type="image/png" medium="image" fileSize="427571">
        <media:title type="plain">Woman taking Amsler grid eye exam</media:title>
      </media:content>
    </item>
    <item>
      <title>Simcere’s rademikibart meets phase III endpoints in atopic dermatitis </title>
      <description>
        <![CDATA[Simcere Pharmaceutical Group Ltd.’s monoclonal antibody, rademikibart (CBP-201), met the primary endpoint in a Chinese phase III study in adults and adolescents with moderate to severe atopic dermatitis. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/729969</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729969-simceres-rademikibart-meets-phase-iii-endpoints-in-atopic-dermatitis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/monoclonal-antibody-mab.webp?t=1713364043" type="image/jpeg" medium="image" fileSize="243312">
        <media:title type="plain">Monoclonal antibody illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Innovent’s IBI-302 meets phase III endpoints in neovascular AMD </title>
      <description>
        <![CDATA[Innovent Biologics Inc.’s efdamrofusp alfa (IBI-302) met the primary endpoint in the phase III Star trial in neovascular age-related macular degeneration (nAMD), and the Suzhou, China-based company will submit an NDA to China’s National Medical Products Administration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729841</guid>
      <pubDate>Wed, 25 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729841-innovents-ibi-302-meets-phase-iii-endpoints-in-neovascular-amd</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Amsler-grid-test.webp?t=1627064994" type="image/png" medium="image" fileSize="427571">
        <media:title type="plain">Woman taking Amsler grid eye exam</media:title>
      </media:content>
    </item>
    <item>
      <title>Kintor’s KX-826 meets phase III endpoints in alopecia  </title>
      <description>
        <![CDATA[Kintor Pharmaceutical Ltd.’s topical androgen receptor antagonist, pyrilutamide (KX-826), met the primary endpoint in a pivotal phase III trial in male androgenetic alopecia, and the company will soon file an NDA with China’s National Medical Products Administration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729893</guid>
      <pubDate>Tue, 24 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729893-kintors-kx-826-meets-phase-iii-endpoints-in-alopecia</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Alopecia.webp?t=1773953185" type="image/jpeg" medium="image" fileSize="1021257">
        <media:title type="plain">Alopecia - hair loss </media:title>
      </media:content>
    </item>
  </channel>
</rss>
